135 related articles for article (PubMed ID: 1684619)
1. Sulfasalazine therapy in psoriatic arthritis: clinical and immunologic response.
Newman ED; Perruquet JL; Harrington TM
J Rheumatol; 1991 Sep; 18(9):1379-82. PubMed ID: 1684619
[TBL] [Abstract][Full Text] [Related]
2. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.
Gupta AK; Grober JS; Hamilton TA; Ellis CN; Siegel MT; Voorhees JJ; McCune WJ
J Rheumatol; 1995 May; 22(5):894-8. PubMed ID: 8587078
[TBL] [Abstract][Full Text] [Related]
3. [Sulfasalazine in rheumatoid arthritis].
Segal R; Caspi D; Sukenik S; Horowitz I; Rubinov A; Fluser D; Scharf Y; Shapira D; Weinberger A; Gedz D
Harefuah; 1991 May; 120(10):577-81. PubMed ID: 1682225
[TBL] [Abstract][Full Text] [Related]
4. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.
Clegg DO; Reda DJ; Abdellatif M
Arthritis Rheum; 1999 Nov; 42(11):2325-9. PubMed ID: 10555027
[TBL] [Abstract][Full Text] [Related]
5. [How to choose a basic drug for psoriatic arthritis?].
Koó E; Seszták M; Gyulai F; Farkas V
Orv Hetil; 1991 Dec; 132(49):2709-12, 2715-6. PubMed ID: 1684842
[TBL] [Abstract][Full Text] [Related]
6. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
7. Treatment of the seronegative spondyloarthropathies with sulfasalazine.
Zwillich SH; Comer SS; Lee E; Erdman WA; Lipsky PE
J Rheumatol Suppl; 1988 Sep; 16():33-9. PubMed ID: 2903925
[TBL] [Abstract][Full Text] [Related]
8. [Acute psychoses in patients with psoriatic arthritis during treatment with sulfasalazine].
Jajić Z; Jajić I
Reumatizam; 1998; 46(1):43-4. PubMed ID: 9921009
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of seronegative oligoarthritis with salazopyrine].
Stroehmann I; Wüstenhagen E; Martini M
Z Rheumatol; 1987; 46(2):79-82. PubMed ID: 2885989
[TBL] [Abstract][Full Text] [Related]
10. Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function.
Diamanti AP; Rosado M; Germano V; Scarsella M; Giorda E; Podestà E; D'Amelio R; Carsetti R; Laganà B
Clin Immunol; 2011 Jan; 138(1):9-13. PubMed ID: 21062675
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
12. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status.
Chalmers IM; Sitar DS; Hunter T
J Rheumatol; 1990 Jun; 17(6):764-70. PubMed ID: 1974926
[TBL] [Abstract][Full Text] [Related]
13. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.
Kraan MC; van Kuijk AW; Dinant HJ; Goedkoop AY; Smeets TJ; de Rie MA; Dijkmans BA; Vaishnaw AK; Bos JD; Tak PP
Arthritis Rheum; 2002 Oct; 46(10):2776-84. PubMed ID: 12384938
[TBL] [Abstract][Full Text] [Related]
14. Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity.
Martin L; Sitar DS; Chalmers IM; Hunter T
J Rheumatol; 1985 Apr; 12(2):270-3. PubMed ID: 2863375
[TBL] [Abstract][Full Text] [Related]
15. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis.
Symmons DP; Salmon M; Farr M; Bacon PA
J Rheumatol; 1988 Apr; 15(4):575-9. PubMed ID: 2899645
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
17. Sulfasalazine therapy for juvenile rheumatoid arthritis.
Imundo LF; Jacobs JC
J Rheumatol; 1996 Feb; 23(2):360-6. PubMed ID: 8882047
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immune response in psoriasis and psoriatic arthritis.
Ventura M; Colizzi M; Ottolenghi A; Polignano A; Sinisi DA; Rantuccio F; Antonaci S; Bonomo L
Recenti Prog Med; 1989 Sep; 80(9):449-54. PubMed ID: 2687984
[TBL] [Abstract][Full Text] [Related]
19. [Changes in the blood picture in sulfasalazine therapy of rheumatoid arthritis].
Rave O
Z Rheumatol; 1987; 46(2):86-91. PubMed ID: 2885991
[TBL] [Abstract][Full Text] [Related]
20. [Psoriatic onycho-pachydermo- periostitis].
Anders HJ; Sanden S; Krüger K
Z Rheumatol; 2002 Oct; 61(5):601-4. PubMed ID: 12399890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
